Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins

Prostaglandins and Other Lipid Mediators

Volumn 106-107, Issue , 2013, Pages 1-7

  Orie, N N ^a,d   Ledwozyw, A ^a,b   Williams, D J ^b   Whittle, B J ^c   Clapp, L H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d ASPETAR ORTHOPAEDIC AND SPORTS MEDICINE HOSPITAL   (Qatar)

Author keywords

Iloprost; IP receptor agonists; MRE 269; Prostacyclin analogues; Prostanoid IP receptors; Rat distal pulmonary arteries; Treprostinil

Indexed keywords

ILOPROST; MRE 269; PROSTACYCLIN RECEPTOR; SELEXIPAG; TREPROSTINIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG RESPONSE; FEMALE; LUNG BLOOD VESSEL; LUNG PARENCHYMA; MALE; NONHUMAN; PULMONARY ARTERY; PULMONARY VEIN; RAT; SPRAGUE DAWLEY RAT;

ILOPROST; IP RECEPTOR AGONISTS; MRE-269; PROSTACYCLIN ANALOGUES; PROSTANOID IP RECEPTORS; RAT DISTAL PULMONARY ARTERIES; TREPROSTINIL;

ACETAMIDES; ACETATES; ANIMALS; BENZOFURANS; BENZYL COMPOUNDS; EPOPROSTENOL; FEMALE; ILOPROST; IMIDAZOLES; MALE; PROPIONATES; PULMONARY ARTERY; PULMONARY VEINS; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, EPOPROSTENOL; VASODILATION;

EID: 84881273691     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2013.07.003     Document Type: Article

References (33)

1. M. Gomberg-Maitland, and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur Respir J 31 2008 891 901
2. N. Skoro-Sajer, I. Lang, and R. Naeije Treprostinil for pulmonary hypertension Vasc Health Risk Manag 4 2008 507 513 (Pubitemid 352037912)
3. J.L. Vachiery Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy Adv Ther 28 2011 251 269
4. G. Simonneau, A. Torbicki, and M.M. Hoeper Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension Eur Respir J 40 2012 874 880
5. S. Narumiya, Y. Sugimoto, and F. Ushikubi Prostanoid receptors: structure, properties, and functions Physiol Rev 79 1999 1193 1226 (Pubitemid 29473315)
6. D.F. Woodward, R.L. Jones, and S. Narumiya International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress Pharmacol Rev 63 2011 471 538
7. 2 agonist Biochem Pharmacol 84 2012 68 75
8. L. Jin, S. Lin, and H. Rong Structural basis for iloprost as a dual peroxisome proliferator-activated receptor α/δ agonist J Biol Chem 286 2011 31473 31479
9. Z.S. Katusic, A.V. Santhanam, and T. He Vascular effects of prostacyclin: does activation of PPAR delta play a role Trends Pharmacol Sci 33 2012 559 564
10. K. Kuwano, A. Hashino, and T. Asaki 2-[4-[(5,6-diphenylpyrazin-2-yl) (isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug J Pharmacol Exp Ther 322 2007 1181 1188 (Pubitemid 47295780)
11. K. Morrison, R. Ernst, P. Hess, R. Studer, and M. Clozel Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function J Pharmacol Exp Ther 335 2010 249 255
12. K. Morrison, R. Studer, R. Ernst, F. Haag, K. Kauser, and M. Clozel Differential effects of selexipag and prostacyclin analogs in rat pulmonary artery J Pharmacol Exp Ther 343 2012 547 555
13. L. Walch, C. Labat, J.P. Gascard, M.V. de, C. Brink, and X. Norel Prostanoid receptors involved in the relaxation of human pulmonary vessels Br J Pharmacol 126 1999 859 866 (Pubitemid 29103701)
14. 4 receptor subtype Br J Pharmacol 154 2008 1631 1639
15. X. Norel Prostanoid receptors in the human vascular wall Sci World J 7 2007 1359 1374 (Pubitemid 47435435)
16. 4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension Am J Respir Crit Care Med 178 2008 188 196 (Pubitemid 351957777)
17. K. Kuwano, A. Hashino, K. Noda, K. Kosugi, and K. Kuwabara A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6- diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its active form, {4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (MRE-269), on rat pulmonary artery J Pharmacol Exp Ther 326 2008 691 699
18. M. Abramovitz, M. Adam, and Y. Boie The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs Biochim Biophys Acta 1483 2000 285 293 (Pubitemid 30029060)
19. 2 prostanoid receptor subtypes Eur J Pharmacol 340 1997 227 241 (Pubitemid 28022647)
20. 2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor Prostaglandins Other Lipid Mediat 2013 10.1016/j.prostaglandins.2013.07.001
21. K.R. Bley, A. Bhattacharya, and D.V. Daniels RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists Br J Pharmacol 147 2006 335 345 (Pubitemid 43214691)
22. 2 receptor agonist cicaprost via a cyclic AMP-independent mechanism Cardiovasc Res 69 2006 107 115 (Pubitemid 41814816)
23. M.R. Maclean, G. Sweeney, M. Baird, K.M. Mcculloch, M. Houslay, and I. Morecroft 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats Br J Pharmacol 119 1996 917 930 (Pubitemid 26366487)
24. B.W. Christman, C.D. McPherson, and J.H. Newman An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension N Engl J Med 327 1992 70 75
25. Y. Li, M. Connolly, and C. Nagaraj Peroxisome proliferator-activated receptor-beta/delta, the acute signaling factor in prostacyclin-induced pulmonary vasodilation Am J Respir Cell Mol Biol 46 2012 372 379
26. 3 receptors Eur J Pharmacol 654 2011 258 265
27. S.M. Wilson, N.A. Sheddan, R. Newton, and M.A. Giembycz Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release Mol Pharmacol 79 2011 586 595
28. J.E. Merritt, T.J. Hallam, and A.M. Brown Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor Br J Pharmacol 102 1991 251 259
29. T. Murata, F. Ushikubi, and T. Matsuoka Altered pain perception and inflammatory response in mice lacking prostacyclin receptor Nature (London) 388 1997 678 682 (Pubitemid 27366439)
30. E. Falcetti, S.M. Hall, and P.G. Phillips Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension Am J Respir Crit Care Med 182 2010 1161 1170
31. R.L. Jones, H. Wise, R. Clark, R.L. Whiting, and K.R. Bley Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations Br J Pharmacol 149 2006 110 120 (Pubitemid 44299074)
32. L.M. Ayer, S.M. Wilson, S.L. Traves, D. Proud, and M.A. Giembycz 4,5-dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) is a selective, pseudo-irreversible orthosteric antagonist at the prostacyclin (IP)-receptor expressed by human airway epithelial cells: IP-receptor-mediated inhibition of CXCL9 and CXCL10 release J Pharmacol Exp Ther 324 2008 815 826 (Pubitemid 351185859)
33. 4) and prostacyclin (IP) receptors Eur J Pharmacol 661 2011 42 48